Brief: Aim Immunotech Reports Third Quarter 2025 Financial Results And Highlights Continued Progress Across Pipeline With Strategic Focus On Pancreatic Cancer Clinical Program
18/11/2025 14:00
AIM ImmunoTech Inc AIM.A: AIM IMMUNOTECH REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS CONTINUED PROGRESS ACROSS PIPELINE WITH STRATEGIC FOCUS ON PANCREATIC CANCER CLINICAL PROGRAM Source text: ID:nGNXQ41Bb Further company coverage: AIM.A
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential